Previous study demonstrated that HH signaling activation was present in a subset of GBM tumors, and SMO inhibition was effective in glioma lines highly expressing Gli1, indicating HH signaling is likely to be a driver in a subset of GBMs [13]. The gene discussed is SMO; the disease is glioblastoma.